Announcements Trials
Browse Landscape

Phase

Phase 2 8Phase NA 2Phase 4 1Phase 2/3 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Gliosarcoma 1

Interventions

Cisplatin 22Magnetic Resonance Spectroscopy 18Gemcitabine 15Carboplatin 14pembrolizumab 13Specimen Handling 13Paclitaxel 13Radiotherapy 10Nivolumab 10Bevacizumab 10atezolizumab 8Radiation 8Platinum 8Pemetrexed 8Doxorubicin 8Docetaxel 81,2-diaminocyclohexaneplatinum II citrate 8Drug Therapy 7Dexamethasone 7Temozolomide 6Rituximab 6Radiotherapy, Intensity-Modulated 6Prednisone 6Surgical Procedures, Operative 5Ipilimumab 5Immunoglobulin G 5Disulfides 5Cytarabine 5Cyclophosphamide 5Biopsy 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × Contrast Media × 90 days × Clear all
NCT04396860 2026-04-22

Testing the Use of the Immunotherapy Drugs Ipilimumab and Nivolumab Plus Radiation Therapy Compared to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Unmethylated Glioblastoma

National Cancer Institute (NCI)

Phase 2/3 Completed
159 enrolled 17 charts
Sarcoma

Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡